Clinical trials: IgA Nephropathy
Primary IgA-nephropathy, High-risk
Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy
The open-label prospective non-randomised controlled aims to assess the efficacy of the combination of immunosupression (IST) and tonsillectomy (TE) in Caucasian patients at high risk of the IgA-nephropathy.
- Conditions
- Primary IgA-nephropathy, High-risk, Caucasians
- Trial name
- NCT07074951
- Testing
- Immunosuppressive treatment, Tonsillectomy
- Where
- 2 sites in Russia
- Volunteers
- 240 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Recurrent IgA Nephropathy
Rituximab in Recurrent IgA Nephropathy
Currently, the treatment options of recurrent IgA nephropathy (IgAN) are conflicting and largely based on expert opinions. Consequently, the recent KDIGO clinical practice guideline for the care of kidney transplant recipients…
- Trial name
- NCT02571842
- Testing
- Intravenous Rituximab, ACEI/ARB and corticosteroids
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Chulalongkorn University
Immunoglobulin A Nephropathy
A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).
- Trial name
- NCT07807995
- Testing
- Povetacicept
- Where
- 4 sites in United States
- Volunteers
- 605 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Chronic Kidney Disease, IgA Nephropathy
Pilot Study of Velcade® in IgA Nephropathy
The primary objective of this study is to investigate the ability of Velcade® (bortezomib) to induce complete or partial remission in patients with severe IgA nephropathy.
- Trial name
- NCT01103778
- Testing
- Bortezomib (Velcade®)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- The Rogosin Institute
Tonsillectomy
Tonsillectomy and Primitive IgA Nephropathy in Children: Strasbourg Cohort and Assessment Practices in Inter North East Region
Primitive kidney disease IgA, represented by Berger's disease and rheumatoid purpura nephropathy, are the first cause of kidney failure from chronic glomerulonephritis: changes in 20 years to end-stage renal failure is described…
- Trial name
- NCT02829164
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Strasbourg, France
Primary IgA Nephropathy
A Trial of HR19042 Capsule in Healthy Chinese Subjects
The study is being conducted to evaluate the safety and pharmacokinetics of HR19042 capsule after single administration in healthy Chinese subjects.
- Trial name
- NCT04887532
- Testing
- HR19042 capsule
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
IGA Glomerulonephritis
Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis
This study evaluates prospectively the effects of an anti-angiotensin II regimen on renal outcome in patients with mesangioproliferative glomerulonephritis followed-up for 10 years.
- Trial name
- NCT01115426
- Testing
- Ramipril or losartan
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University Magna Graecia
Glomerulonephritis, IGA
Study of the IgA Repertoire During IgA Deposition Nephropathy.
IgA plays a major role in mucosal and systemic immunity but retains mysterious and ambivalent aspects. They can thus, depending on the situation, prove to be capable of triggering either a protective inflammatory response or, on…
- Trial name
- ERINA (NCT04092491)
- Testing
- blood sample
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
IgA Nephropathy
A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy
A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.
- Trial name
- NCT05824390
- Testing
- rituximab group
- Where
- China
- Volunteers
- 116 people
- Sponsor
- XIEJINGYUAN
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
- Trial name
- EPPIK (NCT05003986)
- Testing
- Sparsentan
- Where
- 47 sites in United States, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Travere Therapeutics, Inc.
IgA Nephropathy, Chronic Kidney Disease
Nefecon and Ambrisentan in IgA Nephropathy
Application of Budesonide in Combination with Ambrisentan in the treatment of IgA nephropathy with progression ESKD risk (24-hour urinary protein ≥ 0.5g/24h), observing the degree and safety of reducing urinary protein and…
- Conditions
- IgA Nephropathy, Chronic Kidney Disease, Proteinuria
- Trial name
- BAIN (NCT07030894)
- Testing
- "Nefecon®","Ambrisentan"
- Where
- China
- Volunteers
- 129 people
- Sponsor
- The First Hospital of Jilin University
Berger Disease, Bergers Disease
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to <18 years with primary immunoglobulin A nephropathy (IgAN).
- Conditions
- Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
- Trial name
- ADVANCE (NCT07498335)
- Testing
- Drug: Atrasentan
- Where
- 18 sites in United States, China and 5 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Primary Immunoglobulin a Nephropathy (IgAN)
Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in Chinese patients who have completed Nef-301 and continue to be treated with a stable dose of…
- Trial name
- NCT05534919
- Testing
- Nefecon
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Everest Medicines (Singapore) Pte. Ltd.
Immunoglobulin A Nephropathy
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.
- Trial name
- NCT06952426
- Testing
- No intervention, Other treatment, Iptacopan
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Primary IgA Nephropathy
A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
This multicenter, randomized, double-blind, parallel, placebo-controlled study is being conducted to evaluate the efficacy, and safety of HRS-5965 capsule for primary IgA nephropathy.
- Trial name
- NCT07014826
- Testing
- HRS-5965
- Where
- China
- Volunteers
- 378 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
IgA Nephropathy
Steroids Therapy in IgA Nephropathy With Crescents
This prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of steroids therapy for patients of IgA nephropathy with crescents.
- Trial name
- NCT04833374
- Testing
- Methylprednisolone
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Primary Immunoglobulin A Nephropathy (IgAN)
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetics (PK), safety and tolerability (including CV surveillance) of iptacopan in primary immunoglobulin A…
- Trial name
- NCT06994845
- Testing
- iptacopan
- Where
- 20 sites in United States, Argentina and 6 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease
Effect of Statins on IgG, IgA and IgM Level in Chronic Hemodialysis Patients
This is double blind randomized controlled trial on the statins effects on serum IgG, IgA and IgM level in chronic hemodialysis patients in Bandarabbas
- Trial name
- NCT01305317
- Testing
- Lipitor
- Where
- Iran
- Volunteers
- 74 people
- Sponsor
- Hormozgan University of Medical Sciences
Primary IgA Nephropathy
A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
This study aims to evaluate the long-term safety of HRS-5965 capsules in patients with primary IgA nephropathy, and also to assess its efficacy in reducing 24-hour urinary protein and delaying the decline in eGFR in these…
- Trial name
- NCT07582133
- Testing
- HRS-5965 Capsules
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Biopsy-confirmed IgA Nephropathy, Proteinuria Less Than 0.5 g Per Day
Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial
Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. The treatment of IgA nephropathy with normal renal function and minimal proteinuria is unknown.
- Conditions
- Biopsy-confirmed IgA Nephropathy, Proteinuria Less Than 0.5 g Per Day, Normal Blood Pressure, Serum Creatinine Below 120 Umol/l
- Trial name
- NCT01225445
- Testing
- Ramipril
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong